An interventional study of Liquid biopsy in Ethmoid Sinus Tumor, Adenocarcinoma and Circulating Tumor Cell, sponsored by University Hospital, Montpellier. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-19.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Diagnostic
The role of this transversal study is to assess the specificity and sensitivity of liquid biopsy to detect circulating cells tumor of adenocarcinoma of the ethmoid.
Blood sample of participants will be collected at the moment of the surgical procedure or recurrence diagnosis; immediately after surgery; at day 8-10; at month 2-3 of postoperative follow-up.
Two comparison groups will be studied: one age and gender-matched group and one professional exposure-matched group to assess the sensitivity and specificity of liquid biopsy
620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.
This study's planned enrollment of 42 is below the median of 57 across 490 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 224 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liquid biopsy at the inclusion (V0), d8-d10 (V1) and m2-m3 (V2) of postoperative follow-up.
Diagnostic Test: Liquid biopsy
Liquid biopsy at the inclusion (V0) only
Diagnostic Test: Liquid biopsy
Liquid biopsy at the inclusion (V0) only
Diagnostic Test: Liquid biopsy
For cases: 60 mL blood sample (40 ml for CellSave analysis and 20ml for collection) at visit1 then 20 ml for CellSave analysis at visit2 and visit3 For controls: 40 ml (20ml for CellSave analysis and 20ml for collection) at visit1
Number of circulating tumor cell
Presence of at least 1 circulating tumor cell in the liquid biopsies
Time frame: Day0, Day 7 to 10, VMonth 3 for patients ; Day 0 for controls
Number of postoperative circulating tumor cell release
Change of number circulating tumor cells detection in the liquid biopsy after surgery
Time frame: At the surgery
Tumor Node Metastasis (TNM) classification
Description of TNM classification
Time frame: Day 0
Tumor diagnosis
Primary diagnosis or tumor recurrence
Time frame: Day 0
Histological subtype
Description of histological subtype
Time frame: Day 0
Presence of Circulating Tumor Cells (CTCs) in at least one of the patient's peripheral samples
Presence of CTCs in at least one of the patient's peripheral samples
Time frame: at the surgery, day7, month3
Estimated tumour volume
Estimated tumour volume by imaging
Time frame: Day 0
Location of tumour site
Location of tumour site (clinical, during surgery) to be plotted on a diagram
Time frame: Day 0
No study locations are listed for this record.
Start is estimated for Dec 2023; primary completion for Sep 2025, 21 months later.
Of 40 interventional studies with no phase under Adenocarcinoma, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 170. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →